Immune-Metabolic Regulation of Biliary Atresia
Immune-Metabolic Regulation of Biliary Atresia
批准号:
10645435
负责人:
Sarah Ann Taylor
金额:
$11.66万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-15 至 2025-03-31
关键词:
2 year oldATAC-seqAnti-Inflammatory AgentsApoptoticAreaArginineBile fluidBiliaryBiliary AtresiaBiochemical PathwayBiological AssayBiologyCellsCharacteristicsChildhoodCholestasisChromatinClinicalCollaborationsCritical PathwaysDataDiagnosisDiseaseDrainage procedureEarly identificationEpigenetic ProcessFoundationsFreezingFutureGene ExpressionGene Expression ProfileGene Expression RegulationGenesGenetic TranscriptionGranulocyte-Macrophage Colony-Stimulating FactorHepaticHepatocyteHumanImmuneImmune responseInfantInflammatoryLiverMacrophageMeasuresMedicalMentorsMetabolicMetabolismModificationMusNatureNitric Oxide SynthaseObstructionOperative Surgical ProceduresOutcomePathogenesisPathway interactionsPatient-Focused OutcomesPatientsPhenotypePolyaminesPredictive ValuePrognostic MarkerPutrescineROC CurveRegulationResearchResearch PersonnelRheumatologyRoleRunningSamplingSerumSpermidineSpermineSurvival RateTimeTransplantationTransposaseUp-RegulationValidationcell dedifferentiationcohortdifferential expressionepigenetic regulationhydrophilicityimmunoregulationinfancyinnovationliver transplantationmetabolomicsmonocytenew therapeutic targetnovelprognosticprogramsrecruitsingle nucleus RNA-sequencingsurvival predictiontotal measurement Bilirubintranscriptional reprogrammingtreatment strategyuptake
中文摘要
胆道闭锁(BA)是一种婴儿期胆汁淤积性肝病,
肝移植目前的证据支持的原则,即BA产生于一个异常的
对环境触发的免疫反应然而,疾病的确切机制仍然存在
未知虽然巨噬细胞(M β)与人和鼠BA有关,但M β与人和鼠BA有关。
异构的性质和代谢网络负责亲恢复与亲,
炎性M β极化尚未确定。我们的核心前提是,
与患者结局相关的巨噬细胞特异性免疫代谢特征将导致
新的预后生物标志物和细胞亚群特异性疗法,以延长无移植存活期。
我们是第一个在BA婴儿中确定预后代谢物特征的人,
诊断.我们已经证明血清精氨酸代谢物的明显变化,
多胺增加,在BA婴儿在诊断时,与增加
2岁时自体肝(SNL)生存率,尽管临床指标无基线差异
特色已知多胺可将巨噬细胞重编程为抗炎表型,
部分通过细胞凋亡(即凋亡细胞摄取)。我们的初步数据发现,
具有多胺高代谢特征的患者,
特征性单核细胞样M β(MLM,与
单核细胞)和血清GM-CSF。因此,我们假设招募的MLM促进肝脏
适应胆道梗阻;因此,MLM的代谢和表观遗传重编程,
抗炎表型与2岁时SNL相关。探讨
根据这一假设,我们将:1)确定血清精氨酸代谢物的预后作用,以及2)
鉴定与SNL相关细胞亚群特异性转录表型。
英文摘要
Biliary atresia (BA) is a cholestatic liver disease of infancy and is the leading cause of pediatric
liver transplantation. Current evidence supports the principle that BA arises from an aberrant
immune response to an environmental trigger. However, the exact mechanism of disease remains
unknown. While macrophages (M) have been implicated in both human and murine BA, M are
heterogeneous by nature and the metabolic networks responsible for pro-restorative vs pro-
inflammatory M polarization have not been defined. Our central premise is that identifying
macrophage-specific immune-metabolic signatures associated with patient outcome will lead to
novel prognostic biomarkers and cell-subset specific therapies to prolong transplant-free survival.
We have been the first to identify a prognostic metabolite signature in BA infants at the time of
diagnosis. We have shown that distinct changes in serum arginine metabolites, particularly
increased polyamines, in BA infants at the time of diagnosis was associated with increased
survival with native liver (SNL) at the age of 2 years despite no baseline differences in clinical
characteristics. Polyamines are known to reprogram M to an anti-inflammatory phenotype, in
part through efferocytosis (i.e. apoptotic cell uptake). Our preliminary data found that BA patients
with a polyamine-high metabolic signature had increased hepatic numbers of previously
characterized monocyte-like M (MLM, increased expression for genes associated with
monocytes) and serum GM-CSF. We thereby hypothesize that recruited MLM promote hepatic
adaptation to biliary obstruction; thus, metabolic and epigenetic reprogramming of MLM towards
and anti-inflammatory phenotype will be associated with SNL at 2 years of age. To investigate
this hypothesis, we will: 1) define the prognostic role for serum arginine metabolites, and 2)
identify cell subset specific transcriptional phenotypes associated with SNL.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Macrophage Regulation of Immune Pathogenesis of Biliary Atresia
-
批准号:10543779
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Sarah Ann Taylor
-
依托单位:
Macrophage Regulation of Immune Pathogenesis of Biliary Atresia
-
批准号:10761123
-
项目类别:
-
资助金额:$16.29万
-
财政年份:2021
-
负责人:Sarah Ann Taylor
-
依托单位:
Macrophage Regulation of Immune Pathogenesis of Biliary Atresia
-
批准号:10320943
-
项目类别:
-
资助金额:$16.3万
-
财政年份:2021
-
负责人:Sarah Ann Taylor
-
依托单位:
Immune Modulation of Macrophages in Obstructive Cholestasis
-
批准号:10040905
-
项目类别:
-
资助金额:$24.42万
-
财政年份:2020
-
负责人:Sarah Ann Taylor
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: